{"title":"ASPECTS OF RADIOTHERAPY OF BREAST CANCER METASTASES TO THE BRAIN: A LITERATURE REVIEW","authors":"А. Almabek, D. Kaidarova, V. Kim, I. Khussainova","doi":"10.52532/2663-4864-2022-1-63-56-63","DOIUrl":null,"url":null,"abstract":"Relevance: Breast cancer is one of the most common diseases among women in developed countries worldwide. Breast cancer ranks \nfirst in incidence and third in mortality among malignant neoplasms in women. Despite many advances in breast cancer treatment, the \nprognosis for patients with metastatic breast cancer remains poor. The life expectancy of these patients is usually about one year. The \naccuracy of diagnosis and determining the number and sizes of oligometastases by contrasted brain MRI or PET-CT with methionine \nis vital for effective cancer treatment. The emergence of treatment techniques, such as stereotactic radiosurgery (SRS) and stereotactic \nradiotherapy (SRSR), significantly improved the disease prognosis. The use of high-tech radiation therapy in patients with oligometastases from breast carcinoma improves local control of intracranial lesions, prevents death, maintains the quality of life, and improves \noverall survival. \nThe study aimed to analyze the results of key prospective studies on aspects of radiation therapy for breast cancer metastases to \nthe brain. \nMethods: This review included key randomized trials on using radiation therapy for breast cancer metastases in the brain. The search \nwas conducted in the PubMed database for 2005-2020 by the keywords “radiation therapy,” “breast cancer,” and “brain metastases.” \nResults: Reduced treatment time due to stereotactic radiosurgery and radiotherapy allows for maintaining productive life without expressed neurological symptoms. SRS is efficient in patients with up to five oligometastases in breast cancer. More metastases require total \nbrain exposure, which is a poor prognostic factor. In prospective studies, SRS in breast cancer with brain metastases is recommended to \nimprove the quality of life. \nConclusion: The treatment of breast cancer with brain metastases requires a multidisciplinary approach based on the prevalence of \nthe process, previous therapy, general somatic status, comorbidities, and available therapy options. Systemic therapy for breast cancer \npatients with brain metastases follows several schemes that demonstrate their therapeutic effectiveness.","PeriodicalId":19480,"journal":{"name":"Oncologia i radiologia Kazakhstana","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncologia i radiologia Kazakhstana","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.52532/2663-4864-2022-1-63-56-63","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Relevance: Breast cancer is one of the most common diseases among women in developed countries worldwide. Breast cancer ranks
first in incidence and third in mortality among malignant neoplasms in women. Despite many advances in breast cancer treatment, the
prognosis for patients with metastatic breast cancer remains poor. The life expectancy of these patients is usually about one year. The
accuracy of diagnosis and determining the number and sizes of oligometastases by contrasted brain MRI or PET-CT with methionine
is vital for effective cancer treatment. The emergence of treatment techniques, such as stereotactic radiosurgery (SRS) and stereotactic
radiotherapy (SRSR), significantly improved the disease prognosis. The use of high-tech radiation therapy in patients with oligometastases from breast carcinoma improves local control of intracranial lesions, prevents death, maintains the quality of life, and improves
overall survival.
The study aimed to analyze the results of key prospective studies on aspects of radiation therapy for breast cancer metastases to
the brain.
Methods: This review included key randomized trials on using radiation therapy for breast cancer metastases in the brain. The search
was conducted in the PubMed database for 2005-2020 by the keywords “radiation therapy,” “breast cancer,” and “brain metastases.”
Results: Reduced treatment time due to stereotactic radiosurgery and radiotherapy allows for maintaining productive life without expressed neurological symptoms. SRS is efficient in patients with up to five oligometastases in breast cancer. More metastases require total
brain exposure, which is a poor prognostic factor. In prospective studies, SRS in breast cancer with brain metastases is recommended to
improve the quality of life.
Conclusion: The treatment of breast cancer with brain metastases requires a multidisciplinary approach based on the prevalence of
the process, previous therapy, general somatic status, comorbidities, and available therapy options. Systemic therapy for breast cancer
patients with brain metastases follows several schemes that demonstrate their therapeutic effectiveness.